8-KItem 2.02 · Results of OperationsItem 8.01 · Other EventsItem 9.01 · Financial Statements
Baxter reports 5% third-quarter sales growth and raises 2026 outlook
Filed with the SEC on · Summarized by InvestorsBot
Baxter reported third-quarter 2026 sales of $2.98 billion for the period ended September 30, up 5% on a reported and organic basis, with GAAP diluted EPS of $0.57 and adjusted diluted EPS of $0.58. The company generated $448 million in free cash flow, completed a $600 million cash tender offer that retired $864 million of debt, and raised its full-year 2026 guidance to 4%-5% reported sales growth, 3%-4% organic growth, and adjusted diluted EPS of $2.05-$2.15.